Andrographis için Upper Respiratory Tract Infections

Q: Does Andrographis help with Upper Respiratory Tract Infections?

Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).

Q: How much Andrographis should I take for Upper Respiratory Tract Infections?

Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Andrographis?

Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Sonuç

Key Study Findings

Randomized Controlled Trial n=331 1.0 weeks Double-blind

Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …

Dose: 200 mg/day vs: placebo Outcome: URTI symptom severity Etki: None p = 0.034

Popülasyon: Participants with uncomplicated URTI

Review

A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …

Dose: None vs: None Outcome: URTI symptom severity Etki: None None

Popülasyon: COVID-19/URTI patients

Review

Plant-Based Support of Respiratory Health during Viral Outbreaks.

Dose: None vs: None Outcome: None Etki: None None

Popülasyon: None

Other n=179

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Dose: 60 mg vs: placebo Outcome: None Etki: None p = 0.0053

Popülasyon: None

Meta-Analysis n=1000

Safety of Andrographis paniculata: A systematic review and meta-analysis.

Dose: 95% vs: control Outcome: None Etki: None None

Popülasyon: upper respiratory tract infection

Other

In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.

Dose: 6 μg/mL vs: Control group Outcome: None Etki: None None

Popülasyon: None

Key Statistics

Çalışmalar

800

Katılımcılar

↑

Positive

Derece

Referenced Papers

Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … RCT

Complementary therapies in … 2023 6 atıf

A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. Review

Molecules (Basel, Switzerland) 2022 80 atıf

Plant-Based Support of Respiratory Health during Viral Outbreaks. Other

Journal of agricultural … 2022 9 atıf

Safety of Andrographis paniculata: A systematic review and meta-analysis. Meta-Analysis

Pharmacoepidemiology and drug … 2021 32 atıf

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. Other

Journal of traditional … 2021 9 atıf

In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. Other

Brazilian journal of … 2020 45 atıf

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Other

Cell death & … 2019 160 atıf

A review for the neuroprotective effects of andrographolide in the central nervous system. Review

Biomedicine & pharmacotherapy … 2019 103 atıf

A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … RCT

Phytomedicine : international … 2010 107 atıf

Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Review

Alternative medicine review … 2007 163 atıf

Complementary and alternative medicine for upper-respiratory-tract infection in children. Review

American journal of … 2006 51 atıf

Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Systematic Review

Planta medica 2004 262 atıf

Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. Systematic Review

Journal of clinical … 2004 157 atıf

Respiratory and allergic diseases: from upper respiratory tract infections to asthma. Review

Primary care 2002 56 atıf

Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. RCT

Journal of the … 1990

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

acute:: 400 mg 3x/day for up to 7 days
general:: 200 mg standardized extract (30% andrographolides) 2x/day

Üst sınır: No established UL; short-term use (<14 days)

Araştırmalarda İncelenen Dozajlar

Dozaj	Süre	Etki	N
200 mg/day	1.0 weeks	Positive	331
None	--	Positive	--
None	--	Mixed	--
60 mg	--	Positive	179
95%	--	Neutral	1000
6 μg/mL	--	Positive	--
None	--	Mixed	--
18 G	4.0 weeks	Mixed	--

En iyi alım zamanı: At first sign of symptoms; with meals

Safety & Side Effects

Bildirilen Yan Etkiler

⚠ Gastrointestinal discomfort (nausea, diarrhea)
⚠ Headache
⚠ Fatigue
⚠ Allergic reactions (rare)
⚠ Potential anti-fertility effects (high doses in animal studies)

Bilinen Etkileşimler

● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
● Antihypertensive medications (additive blood pressure lowering)
● Immunosuppressant medications (may counteract immunosuppression)

Tolere edilebilir üst alım: No established UL; short-term use (<14 days)

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Andrographis help with Upper Respiratory Tract Infections?

Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).

How much Andrographis should I take for Upper Respiratory Tract Infections?

Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Andrographis?

Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Related Evidence

Şu durum için diğer içerikler: Upper Respiratory Tract Infections

Vitamin D A Zinc A Beta-Glucan A Vitamin C B Echinacea B Garlic B

Hızlı Değerlendirme

Evidence Strength72%

High confidence

Çalışma Dağılımı

RCT (3)Meta (1)Other (3)

Alternatifleri Karşılaştır

Bu durum için diğer bileşenlerin nasıl karşılaştırıldığını görün.Diğer içeriklerin bu sağlık durumu için nasıl karşılaştırıldığını görün.

Şu durum için tüm içerikleri görüntüle: Upper Respiratory Tract Infections

Daha Fazla Bilgi

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.